Page 1

FOR IMMEDIATE RELEASE Exhibit 99.1 Therapeutics MD ™ TherapeuticsMD Announces Second Quarter 2026 Financial Results BOCA RATON , Fla .-- ( BUSINESS WIRE ) -August 11 , 2026 -- TherapeuticsMD , Inc. ( " TherapeuticsMD " or the " Company " ) ( NASDAQ : TXMD ) , a company that owns rights to pharmaceutical royalties , today reported financial results for the three months ended June 30 , 2026 . Second Quarter 2026 Financial Results Net Income from Continuing Operations • Net income from continuing operations totaled $ 164 thousand , compared to net income of $ 545 thousand for the second quarter of 2025 . License Revenues from Continuing Operations • The Company recorded $ 869 thousand in license revenue for the second quarter of 2026 , compared to $ 952 thousand in license revenue for the second quarter of 2025. The decrease is attributable to changes in sales of licensed products . • Total Operating Expenses from Continuing Operations • Total operating expenses were $ 1.7 million , an increase of $ 38 thousand , or 2.3 % , compared to $ 1.6 million for the second quarter of 2025. The increase is primarily attributable to higher general and administrative expenses and the write - off of patents . Evaluation of Strategic Alternatives • The Company continues to evaluate a variety of strategic alternatives that may include , but are not limited to , an acquisition , merger , other business combination , sale of assets , or other strategic transactions involving the Company . Although the Company is exploring potential strategic alternatives , there can be no assurance of a transaction , a successful outcome of these efforts , or the form or timing of any such outcome . The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary . Balance Sheet • As of June 30 , 2026 , the Company's cash and cash equivalents totaled $ 9.2 million .